id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-P-1617-0006,FDA,FDA-2020-P-1617,Final Response Letter from FDA CDER to E4 Consulting,Other,Denial of Petition,2025-12-12T05:00:00Z,2025,12,2025-12-12T05:00:00Z,,2025-12-12T21:02:24Z,,0,0,09000064b90c915b
FDA-2020-P-1617-0005,FDA,FDA-2020-P-1617,"Determination That BACTROBAN (Mupirocin) Nasal Ointment, 2%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2025-12-12T05:00:00Z,2025,12,2025-12-12T05:00:00Z,,2025-12-12T19:43:45Z,2025-22682,0,0,09000064b90c85b0
FDA-2020-P-1617-0004,FDA,FDA-2020-P-1617,Interim Response letter from FDA CDER to E4 Consulting,Other,Letter(s),2020-12-18T05:00:00Z,2020,12,2020-12-18T05:00:00Z,,2020-12-18T22:57:51Z,,0,0,09000064849a99fd
FDA-2020-P-1617-0003,FDA,FDA-2020-P-1617,Attachment 1 - Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from E4 Consulting,Supporting & Related Material,Background Material,2020-06-25T04:00:00Z,2020,6,,,2020-06-25T16:03:46Z,,0,0,090000648470ba7e
FDA-2020-P-1617-0001,FDA,FDA-2020-P-1617,Citizen Petition from E4 Consulting,Other,Citizen Petition,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2025-12-12T20:06:43Z,,0,0,090000648470b6e8
FDA-2020-P-1617-0002,FDA,FDA-2020-P-1617,Acknowledgment Letter from FDA DMS to E4 Consulting,Other,Acknowledgement Letter/Receipt,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T16:03:31Z,,0,0,090000648470b6e9